Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - EYEGATE PHARMACEUTICALS INC | v459809_exh32x2.htm |
| EX-32.1 - EXHIBIT 32.1 - EYEGATE PHARMACEUTICALS INC | v459809_exh32x1.htm |
| EX-31.2 - EXHIBIT 31.2 - EYEGATE PHARMACEUTICALS INC | v459809_exh31x2.htm |
| EX-31.1 - EXHIBIT 31.1 - EYEGATE PHARMACEUTICALS INC | v459809_exh31x1.htm |
| EX-21.1 - EXHIBIT 21.1 - EYEGATE PHARMACEUTICALS INC | v459809_exh21x1.htm |
| EX-10.19 - EXHIBIT 10.19 - EYEGATE PHARMACEUTICALS INC | v459809_exh10x19.htm |
| 10-K - 10-K - EYEGATE PHARMACEUTICALS INC | v459809_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements of EyeGate Pharmaceuticals, Inc. on Form S-8 (Nos. 333-202207 and 333-209441) and on Form S-3 (No. 333-210557) of our report dated February 23, 2017, on our audits of the Consolidated Financial Statements as of December 31, 2016 and 2015 and for each of the years then ended, which report is included in this Annual Report on Form 10-K, to be filed on or about February 23, 2017. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company’s ability to continue as a going concern.
/s/ EISNERAMPER LLP
New York, New York
February 23, 2017